Abstract
Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.
Original language | English (US) |
---|---|
Pages (from-to) | 379-380 |
Number of pages | 2 |
Journal | Nature Reviews Endocrinology |
Volume | 20 |
Issue number | 7 |
DOIs |
|
State | Published - Jul 2024 |
Externally published | Yes |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology